30.04.2018 14:30:00
|
PTC Therapeutics to Participate at Upcoming Investor Conference
SOUTH PLAINFIELD, N.J., April 30, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the Bank of America Merrill Lynch 2018 Health Care Conference, on Tuesday, May 15th at 2:20 p.m. PT
The presentation will be webcast live on the Events and Presentations page under the investor relations section of PTC Therapeutics' website at www.ptcbio.com and will be archived for 2 weeks following the presentation. It is recommended that users connect to PTC's website several minutes prior to the start of the webcast to ensure a timely connection. PTC's current Investor Presentation are available at the same website location.
About PTC Therapeutics, Inc.
PTC is a science-led, global biopharmaceutical company focused on the discovery, development and commercialization of clinically-differentiated medicines that provide benefits to patients with rare disorders. Founded 20 years ago, PTC Therapeutics has successfully launched two rare disorder products and has a global commercial footprint. This success is the foundation that drives investment in a robust pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need.
FOR MORE INFORMATION PLEASE CONTACT: | |
Media: | Investors: |
Jane Baj | Emily Hill |
+1 (908) 912-9167 | +1 (908) 912-9327 |
View original content:http://www.prnewswire.com/news-releases/ptc-therapeutics-to-participate-at-upcoming-investor-conference-300638566.html
SOURCE PTC Therapeutics, Inc.
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu PTC Therapeutics Incmehr Nachrichten
06.11.24 |
Ausblick: PTC Therapeutics gewährt Anlegern Blick in die Bücher (finanzen.net) | |
07.08.24 |
Ausblick: PTC Therapeutics öffnet die Bücher zum abgelaufenen Quartal (finanzen.net) |
Analysen zu PTC Therapeutics Incmehr Analysen
Aktien in diesem Artikel
PTC Therapeutics Inc | 41,00 | 0,00% |